SUNPHARMA stock news on Anadi Algo News

Thursday, April 30, 2026
DISCLAIMER: AI-generated signals are for informational purposes only. All trading and investment decisions are solely the user's responsibility.|Past performance does not guarantee future results. Trade at your own risk.|Anadi Algo is not a SEBI-registered advisor. Consult a qualified financial advisor before acting on any recommendation.|DISCLAIMER: AI-generated signals are for informational purposes only. All trading and investment decisions are solely the user's responsibility.|Past performance does not guarantee future results. Trade at your own risk.|Anadi Algo is not a SEBI-registered advisor. Consult a qualified financial advisor before acting on any recommendation.|
Stock Landing|82 matching stories

SUNPHARMA Share Price, Latest News & Sentiment

Latest AI-analyzed news for SUNPHARMA, along with saved share-price context, sentiment, quarterly filing summary, and related names in one page.

Stock Coverage Hub

SUNPHARMA News Today

Large-cap stock hub

The banking sector's resilience is crucial for India's economic growth, with credit growth being a key indicator. Current trends suggest healthy asset quality and sustained demand, despite global uncertainties.

Coverage
82
recent stories
Sources
9
distinct publishers
Bias Split
63 bullish / 11 bearish
8 neutral stories
Window
56d
recent coverage span
Saved Quote Snapshot

Sun Pharmaceutical Industries Limited

Last Updated
29 Apr 2026
Price
Rs 1,773
+1.47%
52W Range
Rs 1,548 - Rs 1,851.2
exchange snapshot
PE / VWAP
PE 38.11
VWAP Rs 1,760.6
Trend Read
No trend tag
Saved chart snapshot not available yet.
Business Context
Industry: Pharmaceuticals
Sector Trail: NIFTY 50
Listing Date: 1995-02-08
Market Structure
F&O Eligible: Yes
Indices: NIFTY 50, NIFTY500 SHARIAH, NIFTY ALPHA QUALITY VALUE LOW-VOLATILITY 30
Snapshot Source: mcp+nse
Quarterly Read

Quarter ended 31 Dec 2024

Consolidated results
What This Quarter Says

This is the latest financial report for SUNPHARMA. We don't have previous numbers to compare, so we can't say if things improved or worsened this quarter. This report simply records the company's current financial performance.

Revenue
Rs 13,675 cr
up 120.9% vs previous filing
Profit
Rs 2,918 cr
up 147.0% vs previous filing
EPS / Finance Cost
EPS 12.1
Finance cost Rs 51.51 cr
Filing Context
Filed 1 Feb 2025, 1:03 am
Figures are taken from the saved exchange filing, not from a live request.
Quick Reader Notes
  • Revenue this quarter: Rs 13,675 cr, up 120.9% vs previous filing.
  • Profit this quarter: Rs 2,918 cr, up 147.0% vs previous filing.
  • EPS gives a quick sense of per-share earnings: 12.1.
How To Read This

Treat this block as a saved quarter snapshot. First see whether revenue and profit are improving, then read the latest news below to judge whether recent headlines support that trend or work against it.

SUNPHARMA FAQ

Why is SUNPHARMA in the news right now?

SUNPHARMA has appeared across 82 recent stories from 9 sources, which usually means there is a real flow of fresh headlines rather than a single isolated mention.

Is SUNPHARMA coverage bullish or bearish right now?

SUNPHARMA coverage is currently leaning bullish, with 63 bullish, 11 bearish, and 8 neutral analyzed stories in the recent window.

Which themes are moving with SUNPHARMA?

Recent SUNPHARMA coverage is clustering around Pharmaceuticals and pharma. Related names showing up alongside SUNPHARMA include DRL, LUPIN, CIPLA.

How should I use this SUNPHARMA news page?

Use this page as a coverage hub for SUNPHARMA: start with the latest headlines, then check the dominant themes, related names, and saved market context before you form a trade or watchlist view.

Workflow View

Use SUNPHARMA coverage to build a cleaner watchlist.

A stock page is most useful when it helps you slow down, compare headlines, and separate one-off noise from a repeatable setup.

This is here if you want to go deeper, not as a push.Explore Anadi
Maintain a long bias on quality banking and financial stocks, focusing on those with strong retail and rural exposure, with strict stop-losses below key support levels.|Quick check: HDFCBANK bearish bias (-1.0% 1d), ICICIBANK bearish bias (oversold).
et_companiesabout 13 hours ago

Strata sells Bengaluru’s industrial asset for Rs 35 crore

The Indian commercial real estate sector is showing resilience and attracting significant investment, driven by strong demand for industrial and warehousing spaces. Successful exits like Strata's reinforce positive market sentiment and highlight the potential for capital appreciation.

Bullish+41.990%
5 facts
Consider a long bias on select commercial real estate developers and REITs, focusing on companies with strong balance sheets and a pipeline of income-generating assets, with strict risk management.|Quick check: SUNPHARMA bullish bias (+1.0% 1d), CIPLA bullish bias (overbought).
et_marketsabout 18 hours ago

Stocks to buy in 2026 for long term: Varun Beverages, Sun Pharma among 5 stocks that could give 10-20% return

The pharma sector is currently seeing mixed performance but long-term outlook remains strong due to domestic demand and export potential. FMCG, represented by VBL, benefits from stable consumer demand.

For pharma, look for companies with strong product pipelines and regulatory approvals; for FMCG, focus on market leaders with consistent growth. Maintain strict stop-losses.|Quick check: VBL bullish bias (overbought), SUNPHARMA bullish bias (+1.0% 1d).

Latest SUNPHARMA Stock Coverage

No specific trade setup. Use pre-market reports for directional bias, but confirm with live market data.|Quick check: NIFTY neutral, SUNPHARMA bullish bias (+1.0% 1d).
Bullish for hospital chains; look for companies with strong balance sheets and expansion plans.|Quick check: SUNPHARMA bullish bias (+1.0% 1d), CIPLA bullish bias (overbought).
livemint_companies1 day ago+12.6

Oaktree Capital Accuses BJ’s of Reneging on Tariff Refund Trade

4 facts
No trade setup is implied or advised for Indian markets.|Quick check: SUNPHARMA bullish bias (+1.0% 1d), CIPLA bullish bias (overbought).
livemint_companies1 day ago+12.6

OxyContin maker Purdue Pharmas criminal sentence could be the last step before company dissolves

3 facts
No trade setup is implied or advised for Indian markets.|Quick check: SUNPHARMA bullish bias (+1.0% 1d), CIPLA bullish bias (overbought).
Positive sentiment for FMCG sector; look for listed companies with strong brand equity and distribution networks.|Quick check: SUNPHARMA bullish bias (+1.0% 1d), CIPLA bullish bias (overbought).
Positive outlook for Maruti Suzuki; potential for stock appreciation on future growth prospects.|Quick check: MARUTI bearish bias (-2.5% 1d), SUNPHARMA bullish bias (+1.0% 1d).
Positive sentiment for the stock; watch for increased trading volumes post-split.|Quick check: SUNPHARMA bullish bias (+1.0% 1d), CIPLA bullish bias (overbought).
livemint_companies1 day ago+27.6

Monarch Networth raises ₹100 crore for PMS fund; reports 10.72% return since launch

5 facts
Monitor listed asset management companies for potential positive sentiment spillover.|Quick check: SUNPHARMA bullish bias (+1.0% 1d), CIPLA bullish bias (overbought).
Long ZOMATO, anticipating continued growth in non-food delivery segments and improved profitability.|Quick check: ZOMATO neutral, SUNPHARMA bullish bias (+1.0% 1d).
Long positions in export-oriented textile, leather, and pharmaceutical companies. Focus on companies with established international presence or strong product portfolios.|Quick check: ARVIND neutral, BATAINDIA neutral (-0.7% 1d).
Positive long-term bias for medical device manufacturers and distributors.|Quick check: SUNPHARMA bullish bias (+1.0% 1d), CIPLA bullish bias (overbought).
Mixed; positive for developers with strong domestic focus, but overall sector sentiment might be tempered by the institutional investment decline.|Quick check: SUNPHARMA bullish bias (+1.0% 1d), CIPLA bullish bias (overbought).
et_companies1 day ago+12.6

Vande Bharat to link Jammu and Srinagar capitals: Omar Abdullah hails ‘all-weather’ rail push

4 facts
Neutral for infrastructure stocks; await concrete project announcements.|Quick check: SUNPHARMA bullish bias (+1.0% 1d), CIPLA bullish bias (overbought).
Consider accumulating quality stocks in infrastructure, manufacturing, and financial sectors on dips, maintaining a long-term investment horizon.|Quick check: NIFTY neutral, SUNPHARMA bullish bias (+7.0% 1d).
Maintain a neutral to slightly cautious bias on established consumer durable stocks until the impact of new entrants like Urban Company becomes clearer; look for potential opportunities in ancillary industries.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), CIPLA bullish bias (overbought).
Maintain a bullish bias on Indian EMS stocks, focusing on companies with strong order books and diversified product portfolios, with a long-term investment horizon.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), CIPLA bullish bias (overbought).
Maintain a bullish bias on auto ancillary stocks with strong R&D and M&A activity in EV components, with a focus on companies demonstrating clear growth strategies in this segment.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), CIPLA bullish bias (overbought).
Maintain a bullish bias on SUNPHARMA, looking for entry points on minor pullbacks, with strict risk management around key support levels.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), CIPLA bullish bias (overbought).
Maintain a bullish bias on SUNPHARMA, looking for consolidation or dips as potential entry points, with a focus on long-term growth prospects.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), CIPLA bullish bias (overbought).
Maintain a bullish bias on quality banking and NBFC stocks, focusing on those with strong asset quality and consistent credit growth. Consider long positions with strict stop-losses.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), VBL bullish bias (overbought).
Consider a long bias on established Indian FMCG companies with strong balance sheets and a history of strategic acquisitions, anticipating further M&A activity in the D2C space.|Quick check: DABUR bullish bias (overbought), SUNPHARMA bullish bias (+7.0% 1d).
Maintain a bullish bias on well-managed retail stocks with strong fundamentals and growth prospects, focusing on companies demonstrating consistent profitability and shareholder-friendly policies.|Quick check: TRENT neutral (overbought), SUNPHARMA bullish bias (+7.0% 1d).
Bullish bias for NTPC and SUNPHARMA; look for long opportunities with defined risk.|Quick check: NTPC bullish bias (overbought), SUNPHARMA bullish bias (+7.0% 1d).
Maintain a bullish bias on SUNPHARMA, looking for consolidation after the initial rally, with a focus on long-term growth from the biosimilar segment. Consider short-term caution on LUPIN and BIOCON if M&A concerns resurface.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), LUPIN neutral (+1.0% 1d).
Bullish bias for Sun Pharma and Shyam Metalics; look for entry points on minor pullbacks or breakout confirmations.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), SHYAMMETL bullish bias (+8.2% 1d).
No specific trade setup; use for daily market preparation.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), CIPLA bullish bias (overbought).
Bullish for financial services and sectors attracting foreign investment.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), CIPLA bullish bias (overbought).
Strong bullish bias for Sun Pharma; consider long positions with a focus on integration success.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), CIPLA bullish bias (overbought).
Bullish for Sun Pharma; focus on long-term growth from new therapeutic areas and geographies.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), CIPLA bullish bias (overbought).
Bullish for Sun Pharma's long-term growth prospects in the biosimilar segment.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), CIPLA bullish bias (overbought).
Positive bias for large-cap pharma stocks with global ambitions; watch for further consolidation.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), CIPLA bullish bias (overbought).
Neutral for Indian pharma; no direct trading action based on this news for Indian-listed stocks.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), CIPLA bullish bias (overbought).
Positive bias for SUNPHARMA, but with an eye on execution risks. Consider long-term positions.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), CIPLA bullish bias (overbought).
Slight negative bias for INDIGO in the very short term; watch for prolonged disruptions.|Quick check: INDIGO neutral (+1.1% 1d), SUNPHARMA bullish bias (+7.0% 1d).
Bullish for Monarch Networth Capital; potential for increased revenue and market share.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), CIPLA bullish bias (overbought).
Maintain a bullish bias on fundamentally strong pharma companies with a clear global expansion strategy, using dips as accumulation opportunities.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), COFORGE bearish bias (+4.3% 1d).
Consider a bullish bias for select pharma stocks with strong pipelines and export exposure; maintain strict stop-losses below recent support levels.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), VBL bullish bias (overbought).
Maintain a bullish bias on banking stocks with strong asset quality and deposit growth, but exercise risk discipline by setting stop-losses below recent support levels.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), RELIANCE bullish bias (+3.0% 1d).
Maintain a bullish bias on SUNPHARMA, but monitor for potential integration challenges and debt implications post-acquisition. Consider long positions with defined risk management.|Quick check: SUNPHARMA bearish bias (-3.6% 1d), DRL neutral.
Maintain a bullish bias on quality banking stocks with strong asset quality and credit growth, while exercising caution on NBFCs due to valuation concerns.|Quick check: SUNPHARMA bearish bias (-3.6% 1d), PAYTM neutral (-0.9% 1d).
For SUNPHARMA, maintain a 'wait and watch' approach post-initial rally, focusing on integration news and debt management. Consider long positions only after clear signs of successful integration and debt reduction.|Quick check: SUNPHARMA bearish bias (-3.6% 1d), CIPLA bullish bias (overbought).
Maintain a bullish bias on large-cap Indian pharma stocks with strong R&D and M&A capabilities, setting stop-losses below recent support levels.|Quick check: SUNPHARMA bearish bias (-3.6% 1d), DRL neutral.
Maintain a bullish bias on large-cap pharma stocks with strong international exposure and a clear M&A strategy, while exercising risk discipline.|Quick check: SUNPHARMA bearish bias (-3.6% 1d), CIPLA bullish bias (overbought).
Maintain a bullish bias on large-cap Indian pharma companies with strong M&A strategies, but always use stop-losses to manage event-driven risks.|Quick check: SUNPHARMA bearish bias (-3.6% 1d), CIPLA bullish bias (overbought).
Look for long opportunities in the mentioned stocks, especially if they open strong and sustain momentum.|Quick check: RELIANCE bearish bias (-1.0% 1d), PAYTM neutral (-0.9% 1d).
Look for long opportunities in SUNPHARMA, anticipating positive re-rating due to strategic acquisition. Monitor integration risks.|Quick check: SUNPHARMA bearish bias (-3.6% 1d), CIPLA bullish bias (overbought).
Maintain a bullish bias on large-cap Indian pharma stocks, particularly those with strong balance sheets and global ambitions, with a focus on M&A-driven growth. Risk discipline is crucial given the high debt component in such large deals.|Quick check: SUNPHARMA bearish bias (-3.6% 1d), DRL neutral.
Consider long positions in SUNPHARMA, anticipating positive sentiment from this strategic move.|Quick check: SUNPHARMA neutral (+0.7% 1d), CIPLA bullish bias (overbought).
Adopt a cautious to bearish stance on the pharma sector, favoring companies with strong R&D pipelines and diversified revenue streams.|Quick check: SUNPHARMA bearish bias (+0.0% 1d), CIPLA neutral (+0.4% 1d).
Neutral; observe SUNPHARMA's price and volume for potential trading opportunities based on live market data.|Quick check: SUNPHARMA bearish bias (+0.0% 1d), CIPLA neutral (+0.4% 1d).
Negative bias for pharma stocks; consider short positions or reducing exposure until clarity emerges.|Quick check: SUNPHARMA bearish bias (+0.0% 1d), CIPLA neutral (+0.4% 1d).
Consider a 'buy on dips' strategy for pharma companies with strong backward integration or diversified sourcing, but with strict stop-losses due to input cost volatility.|Quick check: SUNPHARMA bearish bias (+0.0% 1d), AUROPHARMA bullish bias (-1.4% 1d).
Focus on stock-specific opportunities in large-cap names; consider long positions on positive news.|Quick check: LIC neutral, MARUTI bullish bias (+1.0% 1d).
Positive sentiment for SUNPHARMA; potential for minor upside.|Quick check: SUNPHARMA bearish bias (-3.5% 1d), CIPLA neutral (+0.4% 1d).
Monitor other large-cap pharma stocks for contagion, but focus on company-specific news for Sun Pharma. Maintain a cautious stance.|Quick check: SUNPHARMA bearish bias (+0.1% 1d), CIPLA neutral (+0.7% 1d).
Consider a positive bias for Sun Pharma, but also factor in the debt burden or equity dilution associated with such a large acquisition.|Quick check: SUNPHARMA bearish bias (+0.1% 1d), CIPLA neutral (+0.7% 1d).
For banking stocks, look for opportunities in fundamentally strong banks with improving asset quality and credit growth, but be mindful of deposit pricing pressures. Consider Bank of India as a potential buy based on expert recommendation.|Quick check: AVANTIFEED neutral, INDUSTOWER bullish bias (+3.6% 1d).
Look for entry points in auto stocks on minor dips, and for pharma, focus on companies with strong domestic strategies or specific product advantages.|Quick check: JUBILANTPHAR neutral, PIRAMALPH neutral.
Maintain a cautious stance on pharma stocks with high branded drug exposure; consider defensive plays or companies with strong domestic focus and diversified product pipelines.|Quick check: VEDL bullish bias (+1.4% 1d), NATIONALUM bullish bias (+0.1% 1d).
Focus on Indian pharma companies with strong generic pipelines or those less exposed to patented drugs in the US, while being cautious on specialty pharma players.|Quick check: SUNPHARMA bearish bias (oversold), CIPLA bearish bias (oversold).
Look for pharma companies with strong R&D, backward integration into APIs, and a growing export footprint; consider accumulating on dips with a medium to long-term horizon.|Quick check: SUNPHARMA bearish bias (oversold), LUPIN bearish bias (-0.4% 1d).
Look for opportunities in large-cap and mid-cap pharma stocks with strong export footprints, anticipating a positive impact on their top and bottom lines due to reduced logistics costs and increased market reach.|Quick check: SUNPHARMA bearish bias (oversold), HDFCBANK neutral (+0.9% 1d).
Look for long positions in established Indian pharmaceutical companies with diversified product portfolios and strong export revenues, maintaining a stop-loss below recent support levels.|Quick check: SUNPHARMA bearish bias (oversold), LUPIN bearish bias (-0.4% 1d).
Maintain a bearish bias on Indian pharma stocks with high US exposure; look for short opportunities on any relief rallies, with strict stop-losses.|Quick check: SUNPHARMA bearish bias (oversold), CIPLA bearish bias (oversold).
Consider a short position on Sun Pharma or reduce long exposure, especially if tariff news is confirmed.|Quick check: SUNPHARMA bearish bias (oversold), CIPLA bearish bias (oversold).
Maintain a bearish bias on Indian pharma stocks; look for shorting opportunities or avoid fresh long positions until tariff uncertainty subsides.|Quick check: SUNPHARMA bearish bias (-1.8% 1d), CIPLA bearish bias (oversold).
Maintain a bullish bias on Indian pharma stocks focusing on chronic disease segments, with a disciplined approach to entry points and risk management.|Quick check: AJANTPHARM bearish bias (-2.6% 1d), SUNPHARMA neutral (-0.3% 1d).
Maintain a bullish bias on select Indian pharma stocks with strong R&D and manufacturing capabilities for generics, focusing on those entering high-growth therapeutic areas like GLP-1s.|Quick check: SUNPHARMA bullish bias (+2.7% 1d), LUPIN bullish bias (+0.8% 1d).
Bullish on healthcare; look for dips to accumulate quality stocks.|Quick check: APOLLOHOSP bullish bias (+2.2% 1d), LUPIN bullish bias (+0.8% 1d).
Bearish bias on API and bulk drug manufacturers; cautious on integrated pharma companies due to potential margin pressure.|Quick check: SUNPHARMA neutral (+0.3% 1d), CIPLA bearish bias (oversold).
Look for early indicators of market penetration and prescription growth for the listed pharma companies; a long bias could be considered for those demonstrating strong initial sales, with risk managed by monitoring competitive pricing pressures.|Quick check: SUNPHARMA neutral (+1.2% 1d), DRL neutral.
Look for entry points in established Indian pharma companies, focusing on those with strong R&D capabilities and global partnerships, with a long-term bullish bias.|Quick check: SUNPHARMA neutral (+1.2% 1d), CIPLA bearish bias (oversold).
Identify Indian pharmaceutical companies that are likely to launch generic semaglutide for potential upside. Be cautious with companies heavily reliant on innovator drugs facing patent cliffs.|Quick check: LUPIN bullish bias (+2.6% 1d), DRL neutral.
Look for short-term volatility in companies entering the generic semaglutide market; consider a 'sell on news' approach for competitors if initial pricing is not competitive.|Quick check: NATCOPHARM bullish bias (+1.8% 1d), SUNPHARMA neutral (+1.2% 1d).
Focus on companies with strong distribution networks and efficient manufacturing capabilities to navigate the competitive landscape; consider short-term volatility due to pricing wars.|Quick check: SUNPHARMA neutral (-0.7% 1d), ZYDUSLIFE neutral (+1.2% 1d).
Monitor Sun Pharma for upward momentum; a successful approval could lead to a sustained rally, while any delays or rejections would be a negative catalyst.|Quick check: SUNPHARMA neutral (-1.4% 1d), CIPLA bearish bias (-1.4% 1d).
Look for entry points in the mentioned stocks, potentially on dips, with appropriate stop-losses.|Quick check: INFY bearish bias (oversold), PRAJIND neutral (+0.8% 1d).
Neutral, as this is historical data. Use it to understand past market dynamics and potential long-term themes.|Quick check: COALINDIA bullish bias (+1.2% 1d), SUNPHARMA bullish bias (overbought).